Panos Xaplanteris provides his take on the results of PERFORM-TAVR presented by Jonathan Afilalo at ACC.24 in Atlanta.

Mirvat Alasnag interviews Javed Butler about the EMPACT-MI trial which he presented at ACC.24 in Atlanta. 

Among patients at increased risk for heart failure after acute MI, treatment with empagliflozin did not lead to a significantly lower risk of first hospitalization for heart failure or death from any...

Luis Ortega-Paz interviews C. Michael Gibson about the AEGIS-II primary trial results which he presented at ACC.24 in Atlanta.

ApoA-I post-heart attack showed no reduction in 90-day death or heart attack risk. However, exploratory analysis hints at benefits at one year, suggesting potential for longer-term efficacy.

Alessandro Sticchi interviews Howard C. Herrmann about the primary outcomes from the randomized SMART Trial which he presented at ACC.24 in Atlanta.

Patients with severe aortic stenosis and small aortic annuli, typically female and often underrepresented in clinical trials, are at risk for impaired valvular hemodynamics and associated...

REDUCE-AMI is a multicentre, registry-based, prospective open-label parallel-group randomised clinical trial evaluating the benefit of beta-blocker treatment in patients with acute MI and an ejection fraction >50% treated with a contemporary reperfusion strategy.

Nicola Ryan and Ali Nazmi Calik provide their take on the results which were presented...

Mirvat Alasnag interviews Jacob Eifer Møller about the results of the DANGER-shock Trial which he presented at the ACC.24 in Atlanta.

Results show that the implantation of microaxial flow pump post-heart attack significantly boosts survival in patients with STEMI-related cardiogenic shock, though with increased complications. The trial's positive...

Elad Asher provides his take on the ULTIMATE-DAPT Trial results which Gregg W Stone presented at ACC.24 in Atlanta.

Aaysha Cader interviews Rasha Al-Lamee and Michael Foley about the results of the ORBITA-COSMIC trial presented at ACC.24 in Atlanta.

Results showed that coronary sinus reducer relieved angina symptoms but lacked evidence of increased blood flow to the heart. While beneficial for refractory angina patients, its mechanism remains...

Luigi Biasco interviews Moritz Seiffert about the one-year outcomes of the randomized DEDICATE-DZHK6 trial which he presented at ACC.24 in Atlanta.

TAVR was found non-inferior to SAVR in low-risk patients, showing decreased rates of death or stroke at one year. The trial supports TAVR's safety and efficacy, highlighting...

Alessandro Sticchi interviews David E. Kandzari about the results of the Target Bp I Randomized Trial which he presented at ACC.24.

The trial reports mixed results on nerve ablation for high blood pressure with a modest but statistically significant difference in lowered blood pressure at 3 months,...

Ali Nazmi Calik provides his take on the results of the PREVENT trial presented at ACC.24 in Atlanta.

Nicola Ryan provides her take on the FULL REVASC trial which was presented at ACC.24 in Atlanta and published Simultaneously in NEJM.

The FULL REVASC trial is a multicentre registry-based randomised control trial comparing FFR-guided complete revascularisation of non-culprit lesions versus culprit lesion PCI alone in patients presenting...

Marco Spagnolo and Daniele Giacoppo report the main results of the IVUS-ACS trial presented by Shao-Liang Chen, from the Nanjing First Hospital, Nanjing Medical University, Nanjing, in a Featured Clinical Research session at ACC.24 in Atlanta and simultaneously published in The Lancet.(1)